Dr. John M. Estess JR., MD
Cardiology (Cardiovascular Disease Physician)
499 Gloster Creek Vlg Ste A2, Cardiology Associates Of North Ms, Pa
Tupelo, MS 38801
Who else practices at this address →
Lee County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Mississippi Medical College (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 3,646
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Mississippi Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MS license 17588
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Mississippi Medical Center Tupelo, MS
- North Mississippi Medical Center-Gilmore Amory Amory, MS
- Clay County Medical Corporation West Point, MS
- Tishomingo Health Services Inc Iuka, MS
- Marion Regional Medical Center Hamilton, AL
Medical groups
- North Mississippi Medical Center Services LLC (29 clinicians)
- North Mississippi Clinics LLC (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 3,646
- Services billed
- 16,286
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12,420 | 125 |
| Injection, inclisiran, 1 mg | 7,384 | 26 |
| Injection, regadenoson, 0.1 mg | 1,568 | 392 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 1,274 | 1,263 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,185 | 825 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 762 | 658 |
| Blood test, clotting time | 612 | 238 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 555 | 555 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 536 | 509 |
| Anticoagulant management of patient taking warfarin | 494 | 216 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 20 payments worth $775 in total to this clinician.
| Thrombolex, Inc. | $186 |
|---|---|
| Boston Scientific Corporation | $161 |
| Bard Peripheral Vascular, Inc. | $134 |
| Abiomed | $103 |
| Amgen Inc. | $63.20 |
| Alnylam Pharmaceuticals Inc. | $40.26 |
| Esperion Therapeutics, Inc. | $19.53 |
| Novo Nordisk Inc | $19.13 |
| Food and Beverage | $775 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $172,055 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - The African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and Black Participants in the US
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.